GlassScriptPhysician profile
Arshad K Nelson
NPI 1205342508
$1,865.95
in general payments reported to CMS, 2019-2025
15 companies · $684 in 2025
The $684 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.03 · 2022: $296 · 2023: $623 · 2024: $204 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.03 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $485.90 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $304.84 | 2022-2024 | Rybelsus |
| Medical Device Business Services, INC. | $287.00 | 2025 | Dermabond |
| Idorsia Pharmaceuticals US INC | $204.37 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $174.21 | 2024-2025 | Fasenra, Airsupra, Farxiga |
| Pfizer INC. | $116.68 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.10 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.20 | 2023-2025 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $28.98 | 2023 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $22.48 | 2023 | |
| Vanda Pharmaceuticals INC. | $19.86 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $19.14 | 2025 | Nucala |
| Currax Pharmaceuticals LLC | $18.01 | 2025 | Contrave |
| Ardelyx, INC. | $17.15 | 2024 | Ibsrela |
| Acadia Pharmaceuticals INC | $15.03 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.